• Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street

    21 days ago - By Xconomy

    Cell therapies and antibody drugs grab much of the attention and investment in cancer drug development but the scientists at Zentalis Pharmaceuticals contend that there's a place for small molecules too. Now the biotech is preparing for an initial public stock offering to advance its pipeline, which includes a lead candidate in testing in combination with a Pfizer drug. Zentalis set a preliminary $100 million target for its IPO, according to documents filed with the Securities and Exchange Commission late Friday. The New York-based company has applied for a Nasdaq listing under the stock...
    Read more ...